| Literature DB >> 31383996 |
Xiujian Wang1,2,3,4, Yongxian Hu1,2,3,4, Xiao Liu5, Jian Yu1,2,3,4, Pengfei Xu6, Guoqing Wei1,2,3,4, Chao Jin6, Wenjun Wu1,2,3,4, Huarui Fu1,2,3,4, Lijuan Ding1,2,3,4, Fang Ni1,2,3,4, Hao Zhang1,2,3,4, Zuyu Liang1,2,3,4, Binsheng Wang1,2,3,4, Xiaoqing Li1,2,3,4, Cong Wei1,2,3,4, Yunyun Deng6, Jimin Shi1,2,3,4, Lei Xiao7, Zhao Wu7, Tao Sun8, He Huang9,10,11,12.
Abstract
Chimeric antigen receptor (CAR) T-cell therapy has displayed potent anti-leukemia activity in acute lymphocytic leukemia (ALL), acting as a new ray of hope to refractory/relapsed patients. However, the influence of CAR-T therapy on host immune system has not been well elucidated. Thus, We applied high-throughput T cell receptor β chain sequencing to track the dynamic change of T-cell repertoire induced by CAR-T therapy in B-cell ALL patients. Six Chinese patients achieving complete remission were under observation, whose blood samples, bone marrow samples and infused CAR-T samples were collected at serial time points before and after CAR-T therapy. We observed decreased TCR diversity and increased clonality of T-cell repertoire in both peripheral blood and bone marrow after CAR-T administration. The persistent T cell clones in blood and bone marrow expanded following leukemic cell destruction and were barely detected in CAR T-cell pool. For the first time, our results demonstrated CAR-T therapy could stimulate the clonal proliferation of CAR-negative T cells in patients. Considering other groups' animal results indicating that CAR-T therapy could facilitate the proliferation of tumor antigen-specific T cells and that the emergence of these T cell clones followed the destruction of leukemic cells, they are most likely tumor antigen-specific.Entities:
Year: 2019 PMID: 31383996 DOI: 10.1038/s41409-019-0625-y
Source DB: PubMed Journal: Bone Marrow Transplant ISSN: 0268-3369 Impact factor: 5.483